| Literature DB >> 24098686 |
Chang Hee Jung1, Min Jung Lee, Jenie Yoonoo Hwang, Jung Eun Jang, Jaechan Leem, Joong-Yeol Park, JungBok Lee, Hong-Kyu Kim, Woo Je Lee.
Abstract
BACKGROUND: Elevated ferritin concentration has been implicated in the etiology of type 2 diabetes. Accumulating evidence, mostly from studies conducted on western populations, has demonstrated a strong association between the elevated ferritin concentrations and incident type 2 diabetes. In Asian populations, however, the longitudinal studies investigating the association of elevated serum ferritin levels and type 2 diabetes are lacking. In present study, we aimed to determine whether elevated serum ferritin levels are related to the incident type 2 diabetes in healthy Korean men. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2013 PMID: 24098686 PMCID: PMC3787082 DOI: 10.1371/journal.pone.0075250
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Selection of study participants.
Baseline clinical and biochemical characteristics of study subjects with respect to incident diabetes during a 4 year period.
| Incident type 2 diabetes | ||||
| No | Yes | |||
| n (%) | 1843 (90.8) | 186 (9.2) |
| Overall |
| Age (yr) | 50.9±8.3 | 54.4±8.3 | <0.001 | 51.2±8.4 |
| BMI (kg/m2) | 24.6±2.8 | 25.8±3.6 | <0.001 | 24.7±2.9 |
| WC (cm) | 84.5±11.8 | 88.2±10.2 | <0.001 | 84.8±11.7 |
| Systolic BP (mmHg) | 121.5±13.1 | 121.6±16.5 | 0.961 | 121.6±13.4 |
| Diastolic BP (mmHg) | 75.5±8.4 | 75.7±9.0 | 0.714 | 75.5±8.5 |
| Current smoker (%) | 30.3 | 35.5 | 0.111 | 30.8 |
| Drinking habits (%) | 76.6/23.4 | 73.1/26.9 | 0.279 | 76.3/23.7 |
| Exercise habits (%) | 48.3/51.7 | 49.5/50.5 | 0.817 | 48.4/51.6 |
| Family historyof diabetes (%) | 21.3 | 18.8 | 0.452 | 21.2 |
| FPG (mg/dl) | 96.2±9.4 | 109.7±12.4 | <0.001 | 97.3±10.3 |
| HbA1c (%) | 5.4 (5.1–5.6) | 5.8 (6.0–6.2) | <0.001 | 5.2 (5.4–5.7) |
| HOMA-IR | 1.7±0.9 | 2.2±1.2 | <0.001 | 1.8±1.0 |
| Total cholesterol(mg/dl) | 193.6±31.6 | 192.7±37.6 | 0.758 | 193.5±32.2 |
| TG (mg/dl) | 123 (89–167) | 141 (99–198) | <0.001 | 125 (90–170) |
| LDL-C (mg/dl) | 126.8±28.8 | 125.3±33.3 | 0.553 | 126.6±29.2 |
| HDL-C (mg/dl) | 53.3±12.4 | 50.6±12.2 | 0.004 | 53.1±12.4 |
| Uric acid (mg/dl) | 5.9±1.2 | 6.0±1.2 | 0.704 | 5.9±1.2 |
| AST (U/L) | 21 (24–30) | 26 (21–34) | 0.010 | 25 (21–30) |
| ALT (U/L) | 23 (17–31) | 25 (19–36) | 0.003 | 23 (18–32) |
| GGT (U/L) | 25 (17–42) | 32 (22–51) | <0.001 | 26 (18–42) |
| hsCRP (mg/dl) | 0.07(0.05–0.12) | 0.08(0.05–0.13) | 0.026 | 0.07(0.05–0.13) |
| Ferritin (mg/dl) | 157.4±89.1 | 185.8±109.4 | 0.001 | 160.0±91.5 |
BMI, body mass index; WC, waist circumference; BP, blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model of insulin resistance; TG, triglycerides; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; AST, aspartate aminotransferase; AST, alanine aminotransferase; GGT, gamma-glutamyltransferase; hsCRP, high sensitive C-reactive protein.
Represented in the following order; ≤3 times/week, ≥4 times/week.
Represented in the following order; ≤2 times/week, ≥3 times/week.
Baseline clinical and biochemical characteristic of study subjects based on serum ferritin quartile categories.
| Q1 (≤97.2 IU/L) | Q2 (97.3–142.6 IU/L) | Q3 (142.7–200.5 IU/L) | Q4 (≥200.6 IU/L) |
| |
| n (%) | 510 (25.1) | 505(24.9) | 508 (25.0) | 506 (24.9) | <0.001 |
| Age (yr) | 52.6±8.4 | 51.2±8.1 | 50.7±8.2 | 50.3±8.6 | <0.001 |
| BMI (kg/m2) | 24.3±2.5 | 24.6±2.6 | 24.7±3.5 | 25.3±2.7 | <0.001 |
| WC (cm) | 83.1±12.7 | 84.3±12.4 | 85.0±10.9 | 86.8±10.4 | 0.003 |
| Systolic BP (mmHg) | 120.7±13.2 | 121.5±13.1 | 120.6±12.7 | 123.4±14.5 | <0.001 |
| Diastolic BP (mmHg) | 74.8±8.5 | 75.5±8.4 | 75.0±8.7 | 76.9±8.2 | 0.867 |
| Current smoker (%) | 29.0 | 32.5 | 30.1 | 31.4 | <0.001 |
| Drinking habits (%) | 82.5/17.5 | 78.0/22.0 | 75.0/25.0 | 69.6/30.4 | 0.072 |
| Exercise habits (%) | 52.4/47.6 | 48.7/51.3 | 48.4/51.6 | 44.1/55.9 | 0.914 |
| Family history ofdiabetes (%) | 21.6 | 20.2 | 21.9 | 20.8 | 0.015 |
| FPG (mg/dl) | 96.3±9.8 | 97.0±10.5 | 97.7±10.5 | 98.2±10.2 | 0.786 |
| HbA1c (%) | 5.4 (5.2–5.7) | 5.4 (5.2–5.6) | 5.4 (5.1–5.7) | 5.4 (5.2–5.7) | <0.001 |
| HOMA-IR | 1.6±0.8 | 1.7±0.8 | 1.8±1.1 | 2.0±1.0 | 0.342 |
| Total cholesterol (mg/dl) | 192.8±35.2 | 191.7±30.0 | 194.7±30.7 | 194.8±32.6 | <0.001 |
| TG (mg/dl) | 111 (84–156) | 124 (90–166) | 123 (89–169) | 139 (100–196) | 0.972 |
| LDL-C (mg/dl) | 126.4±31.1 | 126.3±28.9 | 127.1±27.3 | 126.8±29.4 | 0.023 |
| HDL-C (mg/dl) | 54.0±12.7 | 52.4±12.0 | 53.8±12.6 | 52.1±12.2 | 0.014 |
| Uric acid (mg/dl) | 5.8±1.2 | 5.9±1.2 | 6.0±1.2 | 6.1±1.2 | <0.001 |
| AST (U/L) | 23 (20–28) | 23 (20–29) | 25 (20–30) | 27 (22–34) | <0.001 |
| ALT (U/L) | 21 (16–27) | 22 (17–29) | 23 (18–31) | 28 (21–40) | <0.001 |
| GGT (U/L) | 21 (15–32) | 23 (17–41) | 27 (18–41) | 35 (23–57) | 0.003 |
| hsCRP (mg/dl) | 0.06(0.04–0.12) | 0.07 (0.04–0.12) | 0.07 (0.05–0.12) | 0.08 (0.05–0.14) | – |
| Ferritin (mg/dl) | 68.4±21.1 | 119.3±12.9 | 169.0±16.1 | 283.7±84.9 | 0.003 |
| Incident diabetes (n, %) | 39 (7.6) | 37 (7.3) | 43 (8.5) | 67 (13.2) |
BMI, body mass index; WC, waist circumference; BP, blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model of insulin resistance; TG, triglycerides; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; AST, aspartate aminotransferase; AST, alanine aminotransferase; GGT, gamma-glutamyltransferase; hsCRP, high sensitive C-reactive protein.
Represented in the following order; ≤3 times/week, ≥4 times/week.
Represented in the following order; ≤2 times/week, ≥3 times/week.
Relative risks (RRs) and 95% confidence intervals (CI) for incident type 2 diabetes based on serum ferritin quartile categories during a 4 year period.
| RR (95% CI) | |||||
| Subgroup | Q1 (≤97.2 IU/L) | Q2 (97.3–142.6 IU/L) | Q3 (142.7–200.5 IU/L) | Q4 (≥200.6 IU/L) |
|
| Type 2 diabetes | |||||
| [no/total no. (%)] | 39/510 (7.6) | 37/505 (7.3) | 43/508 (8.5) | 67/506 (13.2) | |
| Unadjusted | 1 | 0.96 (0.60–1.52) | 1.12 (0.71–1.76) | 1.84 (1.22–2.79) | 0.004 |
| Model 1 | 1 | 1.09 (0.62–1.89) | 1.18 (0.69–2.02) | 2.30 (1.37–3.85) | 0.003 |
| Model 2 | 1 | 1.11 (0.64–1.94) | 1.18 (0.69–2.02) | 2.36 (1.41–3.96) | 0.002 |
| Model 3 | 1 | 1.11 (0.63–1.93) | 1.19 (0.69–2.04) | 2.18 (1.28–3.71) | 0.012 |
| Model 4 | 1 | 1.07 (0.61–1.87) | 1.16 (0.67–1.99) | 2.25 (1.34–3.79) | 0.004 |
| Model 5 | 1 | 1.10 (0.63–1.93) | 1.16 (0.67–1.99) | 2.17 (1.27–3.72) | 0.013 |
Model 1: adjusted for age, HbA1c, WC, systolic BP, diastolic BP, drinking, smoking, exercise habits, and family history of diabetes.
Model 2: adjusted for variables in Model 1 plus hsCRP.
Model 3: adjusted for variables in Model 1 plus GGT, AST and ALT.
Model 4: adjusted for variables in Model 1 plus TG, HDL-C, LDL-C, and HOMA-IR.
Model 5: adjusted for overall confounders noted above.